Kendle plans operations center in IndiaCincinnati.com... the downtown-based clinical research organization, Thursday announced the company has received approval to develop of a new operations center in India. ...Kendle to open operations center in IndiaCincinnati Business CourierGujarat's first IT SEZ clicks as Kendle logs on to MindspaceBusiness Standardall 5 news articles »

Kendle Receives Approval From Indian Government to Proceed With Development of ...PR Newswire (press release)Kendle's expansion in the quickly maturing India market reflects the growing importance of the country to the global clinical research market. ...Market Report -- In Play (KNDL)MSN Moneyall 15 news articles »

Kendle opens more Asia-Pacific officesPharmafocus, UKThe new centres - in Kuala Lumpur, Bangkok and Manila - add to a growing stable of locations for Kendle in the Asia-Pacific region, which is among the fastest-growing regions for clinical research. "With more than half of the world's population, ...

MedCity NewsKendle expands clinical research offices throughout Southeast AsiaMedCity News, OHKendle, based in Cincinnati, has operated in Asia since 1998 and already has a total of eight offices in China, India, Singapore and Australia. The company is able to perform all phases of clinical trials throughout the globe, though it performance ...Kendle Expands Asia/Pacific Operations with Opening of Offices in ... PR Newswire (press release)Kendle opens three Asia/Pacific offices Bizjournals.comall 17 news articles

Kendle Expands Asia/Pacific Operations with Opening of Offices in ...PR Newswire (press release), NYKendle's expansion in Asia/Pacific reflects the growing importance of the region to the global clinical research market. Recent research by the Tufts Center for the Study of Drug Development indicates that within the next three years, ...

Kendle makes a Q4 profitOutSourcing-Pharma.com, UK - 2 hours agoKendle's previous financial results have been clouded by amortization charges, expenses and residual debt from the acquisition of the Phase II-IV clinical ...